<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585285</url>
  </required_header>
  <id_info>
    <org_study_id>CHUM-11-233</org_study_id>
    <nct_id>NCT01585285</nct_id>
  </id_info>
  <brief_title>Coronary Artery Bypass Grafting Strategies for the Anterolateral Territory: a Prospective Randomized Clinical Trial</brief_title>
  <acronym>AMI-PONT</acronym>
  <official_title>Composite Arterial and Venous Grafting Strategy Versus Conventional Coronary Artery Bypass Grafting for the Anterolateral Territory: a Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the AMI-PONT trial is to assess whether the results in term of graft patency
      with a novel coronary artery bypass (CABG) strategy, including a saphenous vein bridge to
      distribute the arterial flow of the left anterior mammary artery (LIMA) to all the
      anterolateral territory, are not inferior than a conventional CABG strategy combining
      separated LIMA graft to left anterior descending coronary and vein graft for other target
      vessels of the anterolateral territory.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: This novel surgical design use a composite-sequential venous graft to distribute
      left anterior mammary artery (LIMA) inflow directly to the left anterior descending coronary
      (LAD), but also to the other branches of the anterolateral territory thereby promoting a
      higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft
      (SVG) bridge (LSVB) interposed between the LAD and one (or more) other anterolateral targets,
      with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.

      Objectives. The main objective of the prospective randomized clinical trial AMI-PONT is to
      assess whether a CABG strategy including a LSVB to distribute the LIMA outflow provides
      non-inferior patency rates compared to conventional CABG surgery with separated LIMA graft to
      LAD and SVG to other anterolateral targets.

      Methods. Two hundred adult patients undergoing primary isolated CABG, requiring grafting of
      LAD and at least one other anterolateral target, will be randomized 1:1 in two treatment
      arms: 1) CABG strategy with LSVB; and 2) conventional CABG strategy with LIMA graft to the
      LAD and separate aorto-coronary SVG to other anterolateral targets. Patients will be assessed
      clinically at 30 days, 6 months, one, five and ten years. They will undergo graft patency
      assessment at one and five years using Multi-Slice Computed Tomography. All patients will
      undergo CABG using cardiopulmonary bypass (CPB). Patients will be excluded if they have a
      contraindication to CPB or MSCT graft assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterolateral territory graft patency index</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of patent (non-occluded) distal anastomoses out of the total number of distal anastomoses for anterolateral distribution including the LAD and the other anterolateral territory coronary target assessed by multi-slice computed tomography angiography for all patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of grafts patency taken separately</measure>
    <time_frame>1 and 5 years</time_frame>
    <description>LIMA to LAD graft patency will be specifically assessed in both groups. Since the grafting strategy provides direct perfusion of the LAD by anastomosing on the hood of the SVG anastomosis to the LAD, we do not expect to see a difference between groups for the expected superior LIMA-LAD patency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite clinical outcome</measure>
    <time_frame>30 days, 1, 5 and 10 years</time_frame>
    <description>Occurrence of the composite outcome of total mortality, nonfatal myocardial infarction, or target vessel revascularization (i.e. redo CABG surgery or percutaneous coronary intervention). Each clinical outcome will also be assessed separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>30 days, 1, 5 and 10 years</time_frame>
    <description>Cardiovascular (CV) mortality: all deaths after the first 30 days are considered CV deaths unless a specific non-cardiovascular cause is evident and considered to be the cause of death (e.g. malignancy). Furthermore, patients who die during the index hospitalization but after the initial 30 days period (i.e. long ICU stay with sepsis) will be considered as CV deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of angina</measure>
    <time_frame>30 days, 1, 5 and 10 years</time_frame>
    <description>Recurrence of angina: new onset of typical chest angina with documented ischemia by stress testing (ECG, echocardiography, or nuclear) or persistence of CCS grade ≥2 angina after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterolateral territory graft patency index</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of patent (non-occluded) distal anastomoses out of the total number of distal anastomoses for anterolateral distribution including the LAD and the other anterolateral territory coronary target assessed by multi-slice computed tomography angiography for all patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>LIMA to SVG Bridge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive composite coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) and saphenous vein graft (SVG) Bridge for the anterolateral targets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive conventional coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LIMA to SVG Bridge Technique</intervention_name>
    <description>This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.</description>
    <arm_group_label>LIMA to SVG Bridge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional CABG</intervention_name>
    <description>Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets</description>
    <arm_group_label>Conventional CABG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients who undergo coronary artery bypass grafting (CABG) surgery
        (for single, double or triple vessel disease) will be eligible if they:

          1. require isolated CABG with median sternotomy on at least one left anterior descending
             (LAD) site and another anterolateral target;

          2. provide written informed consent;

          3. are more than 21 years of age.

        Exclusion Criteria: A patient will be excluded from the study if he/she does not fulfill
        the inclusion criteria, the patient or the treating physician refuse the study or if any of
        the following are observed:

          1. concomitant cardiac procedure associated with CABG including valve surgery and
             ascending aorta surgery;

          2. contra-indications to cardiopulmonary bypass (calcified aorta);

          3. unusable left internal mammary artery (LIMA) such as uncorrected subclavian artery
             stenosis, anterior chest trauma, radiation or injury during harvesting precluding the
             use of the LIMA;

          4. concomitant life-threatening disease likely to limit life expectancy to less than 2
             years;

          5. emergency CABG surgery (immediate revascularization for hemodynamic instability
             precluding patient consent);

          6. prior CABG;

          7. severe congestive heart failure with left ventricular ejection fraction less than 30%.

             Other exclusion criteria precluding MSCT include:

          8. moderate to severe renal impairment (estimated glomerular filtration rate, eGFR &lt;50
             mL/min/1.73 m2);

          9. chronic atrial fibrillation (which can preclude ECG-gating during MSCT);

         10. history of severe hypersensitivity to iodinated contrast agents;

         11. known or suspected for pheochromocytoma;

         12. pregnant/lactating female.

             Furthermore, patients may be excluded at the time of MSCT if they are:

         13. in persistent rapid (&gt;100/min) atrial fibrillation or any other cardiac rhythm that
             precludes reliable ECG triggering;

         14. severe congestive heart failure, New York Heart Association (NYHA) Class IV, despite
             coronary revascularization and maximal medical treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis-Mathieu Stevens, MD, PhD (c)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de l'Universite de Montreal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louis-Mathieu Stevens, MD, PhD</last_name>
    <phone>514-890-8131</phone>
    <email>lm.stevens@videotron.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Genevieve Peloquin, MSc</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>14362</phone_ext>
    <email>genevieve.peloquin.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis-Mathieu Stevens, MD, PhD (c)</last_name>
      <phone>514-890-8131</phone>
      <email>lm.stevens@videotron.ca</email>
    </contact>
    <contact_backup>
      <last_name>Genevieve Peloquin, MSc</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>14362</phone_ext>
      <email>genevieve.peloquin.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Louis-Mathieu Stevens, MD, PhD (c)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Noiseux, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Soulez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Chartrand-Lefebvre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samer Mansour, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Prieto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fadi Basile, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Drouin A, Noiseux N, Chartrand-Lefebvre C, Soulez G, Mansour S, Tremblay JA, Basile F, Prieto I, Stevens LM. Composite versus conventional coronary artery bypass grafting strategy for the anterolateral territory: study protocol for a randomized controlled trial. Trials. 2013 Aug 26;14:270. doi: 10.1186/1745-6215-14-270.</citation>
    <PMID>23971858</PMID>
  </reference>
  <reference>
    <citation>Tremblay JA, Stevens LM, Chartrand-Lefebvre C, Chandonnet M, Mansour S, Soulez G, Prieto I, Basile F, Noiseux N. A novel composite coronary bypass graft strategy: the saphenous vein bridge--a pilot study. Eur J Cardiothorac Surg. 2013 Oct;44(4):e302-7. doi: 10.1093/ejcts/ezt388. Epub 2013 Jul 31.</citation>
    <PMID>23904134</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</investigator_affiliation>
    <investigator_full_name>Louis-Mathieu Stevens</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Coronary artery bypass grafting</keyword>
  <keyword>Left internal mammary artery</keyword>
  <keyword>Composite grafting</keyword>
  <keyword>Multislice Spiral Computed Tomography Scanner</keyword>
  <keyword>Graft patency assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Manuscripts, Abstracts, Presentations</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

